Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Crispr-Based Approaches for the Detection and Targeting of Lung Cancer Biomarkers: A New Era in Precision Oncology

View Full Paper
Ask AI
Bookmark
Share

Authors

IMIbtasam MazharMSMaimona SadiaMSMohammad Saleem

Discussion

Loading...

Member takes

Overview

Prospective study finds CRISPR diagnostics achieve 96.7% sensitivity in lung cancer, indicating a step forward for precision oncology.

Key Points

  • The CRISPR-Cas12a assay achieved 96.7% sensitivity and 98.3% specificity for lung cancer detection.
  • Diagnostic comparisons revealed that CRISPR outperformed conventional PCR and next-generation sequencing (NGS).
  • EGFR mutations disruption via CRISPR-Cas9 reduced cell viability by approximately 65%, showcasing its therapeutic potential.
  • These findings suggest that integrating CRISPR tools could transform early diagnosis and tailored treatments in lung cancer.

Cite This Study

Mazhar et al. (2025) studied this question.

synapsesocial.com/papers/68c187269b7b07f3a06112b4https://doi.org/10.71000/25yfnz11
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Application of CRISPR Technology for Early Detection of Lung Cancer2024 · 1 citations
  2. 2CRISPR with a Double Mismatch Guide RNA Enhances Detection Sensitivity for Low-Frequency Single-Base EGFR Mutation in Circulating Cell-Free DNA of Lung Cancer Patients2025 · 4 citations
  3. 3A “turn-on” CRISPR-mediated method using enhanced fluorescent bimetallic DNA nanoclusters for EGFR mutation detection in non-small cell lung cancer2026
  4. 4CRISPR-mediated modulation of EGFR signaling in lung cancer2025
  5. 5Advancements in CRISPR/Cas Technologies for Sensitive Cancer Detection: Mechanisms, Platforms, and Clinical Translation Roadmap2026